Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn’s disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study - Ferrante, M; D’Haens, G; Jairath, V (Lancet, 2024)